mTORC1 syndrome (TorS): unified paradigm for diabetes/metabolic syndrome
Trends in Endocrinology & Metabolism · 2023-03 · 34 (3) · 135-145
DOI: 10.1016/j.tem.2023.01.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2023-03. Verfasst von Jacob Bar-Tana. Beteiligte Einrichtung: Hebrew University Medical School, Jerusalem 91120, Israel. Electronic address: jacobb@ekmd.huji.ac.il. Hauptthemen laut MEDLINE: Metabolic Syndrome, Diabetes Mellitus, Type 2, Insulin Resistance, Hyperglycemia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
'Glucolipotoxicity' and 'insulin resistance' are claimed to drive type 2 diabetes (T2D) and the non-glycemic diseases of the metabolic syndrome (MetS) (obesity, dyslipidemia, hypertension). In line with that, glycemic and/or insulin control are considered to be primary goal in treating T2D/MetS. However, recent standard-of-care (SOC) treatments of T2D, initially designed to control T2D hyperglycemia, appear now to alleviate the cardio-renal and non-glycemic diseases of T2D/MetS independently of glucose lowering and insulin resistance, and in non-T2D patients altogether, calling for an alternative unifying pathophysiology/treatment paradigm for T2D/MetS. This opinion article proposes to replace the current 'glucolipotoxic/insulin-resistance' paradigm of T2D/MetS with an 'mammalian target of rapamycin complex 1 (mTORC1) syndrome' (TorS) paradigm, implying an exhaustive cohesive disease entity driven by an upstream hyperactive mTORC1, and which includes diabetic hyperglycemia, diabetic dyslipidemia, hypertension, diabetic macrovascular and microvascular disease, non-alcoholic fatty liver disease, some cancers, neurodegeneration, polycystic ovary syndrome (PCOS), psoriasis, and others. The TorS paradigm may account for the insulin-resistant glycemic context of TorS, combined with response to insulin of the non-glycemic diseases of TorS. The TorS paradigm may account for the efficacy of current antidiabetic SOC treatments in diabetic and nondiabetic patients. Most importantly, the TorS paradigm may generate novel treatments for TorS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hebrew University Medical School, Jerusalem 91120, Israel. Electronic address: jacobb@ekmd.huji.ac.il.
Zitieren
APA
Bar-Tana, J. (2023). mTORC1 syndrome (TorS): unified paradigm for diabetes/metabolic syndrome. Trends in Endocrinology & Metabolism, 34(3), 135-145. https://doi.org/10.1016/j.tem.2023.01.001
Vancouver
Bar-Tana J. mTORC1 syndrome (TorS): unified paradigm for diabetes/metabolic syndrome. Trends in Endocrinology & Metabolism. 2023;34(3):135-145. doi:10.1016/j.tem.2023.01.001
BibTeX
@article{BarTana2023,
author = {Bar-Tana, Jacob},
title = {mTORC1 syndrome (TorS): unified paradigm for diabetes/metabolic syndrome},
journal = {Trends in Endocrinology & Metabolism},
year = {2023},
volume = {34},
number = {3},
pages = {135--145},
doi = {10.1016/j.tem.2023.01.001}
}
EUVIMED